Skip to main content
SpringerLink
Log in

Contemporary Management of Nonfunctioning Pancreatic Neuroendocrine Tumors

  • Review Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

This article reviews the current literature and recommendations pertaining to the management of nonfunctioning pancreatic neuroendocrine tumors.

Discussion

In recent years the detection of nonfunctioning pancreatic neuroendocrine tumors has increased coincident with the increased use of cross-sectional imaging and is now thought to represent 2–10% of all pancreatic tumors. Improved understanding of the biology and behavior of these heterogeneous tumors is needed to guide therapy. The present review discusses diagnostics, therapeutics including emerging molecular analytics, and surveillance recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469–1492.

    Article  PubMed  CAS  Google Scholar 

  2. Falconi M, Plockinger U, Kwekkeboom DJ et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196–211.

    Article  PubMed  CAS  Google Scholar 

  3. Ito T, Tanaka M, Sasano H et al. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42: 497–500.

    Article  PubMed  Google Scholar 

  4. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083–1092.

    Article  PubMed  Google Scholar 

  5. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15–31.

    Article  PubMed  Google Scholar 

  6. Pais SA, Al-Haddad M, Mohamadnejad M et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc 2010; 71: 1185–1193.

    Article  PubMed  Google Scholar 

  7. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807–1843.

    Article  PubMed  Google Scholar 

  8. Kulke MH, Siu LL, Tepper JE et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29: 934–943.

    Article  PubMed  CAS  Google Scholar 

  9. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395–401.

    Article  PubMed  CAS  Google Scholar 

  10. Ekeblad S, Skogseid B, Dunder K et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798–7803.

    Article  PubMed  CAS  Google Scholar 

  11. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429: 323–333.

    Article  PubMed  Google Scholar 

  12. Jensen RT. Natural history of digestive endocrine tumors. Paris, France: John Libbey Eurotext Publishing Co. 1999.

    Google Scholar 

  13. Madeira I, Terris B, Voss M et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43: 422–427.

    Article  PubMed  CAS  Google Scholar 

  14. Chu QD, Hill HC, Douglass HO, Jr. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9: 855–862.

    Article  PubMed  Google Scholar 

  15. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62 Suppl 1: 51–58.

    Article  PubMed  Google Scholar 

  16. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002; 9: 67–79.

    PubMed  Google Scholar 

  17. Blansfield JA, Choyke L, Morita SY et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142: 814–818; discussion 818 e811–812.

    Article  PubMed  Google Scholar 

  18. O'Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90: 194–202.

    Article  PubMed  Google Scholar 

  19. Oberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000; 482: 329–337.

    Article  PubMed  CAS  Google Scholar 

  20. Panzuto F, Severi C, Cannizzaro R et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004; 27: 6–11.

    PubMed  CAS  Google Scholar 

  21. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90: 167–183.

    Article  PubMed  CAS  Google Scholar 

  22. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87–109.

    Article  PubMed  Google Scholar 

  23. Diehl DL, Blansfield J, Li J. Cystic pancreatic neuroendocrine tumor. Gastrointest Endosc 2010; 71: 1064–1065; discussion 1065.

    Article  PubMed  Google Scholar 

  24. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69–85.

    Article  PubMed  CAS  Google Scholar 

  25. Lebtahi R, Cadiot G, Sarda L et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38: 853–858.

    PubMed  CAS  Google Scholar 

  26. Alexander HR, Fraker DL, Norton JA et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228–238.

    Article  PubMed  CAS  Google Scholar 

  27. Hellman P, Andersson M, Rastad J et al. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000; 24: 1353–1360.

    Article  PubMed  CAS  Google Scholar 

  28. Norton JA, Kivlen M, Li M et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003; 138: 859–866.

    Article  PubMed  Google Scholar 

  29. Evans DB, Skibber JM, Lee JE et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114: 1175–1181; discussion 1181–1172.

    PubMed  CAS  Google Scholar 

  30. Solorzano CC, Lee JE, Pisters PW et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078–1085.

    Article  PubMed  CAS  Google Scholar 

  31. Warshaw AL, Rattner DW, Fernandez-del Castillo C, Z'Graggen K. Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg 1998; 133: 327–331.

    Article  PubMed  CAS  Google Scholar 

  32. Yamaguchi K, Yokohata K, Ohkido M et al. Which is less invasive—distal pancreatectomy or segmental resection? Int Surg 2000; 85: 297–302.

    PubMed  CAS  Google Scholar 

  33. Sellner F, Thalhammer S, Stattner S et al. TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas—a single-institution experience. J Surg Oncol 2011.

  34. Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776–783; discussion 783–775.

    Article  PubMed  Google Scholar 

  35. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–445.

    Article  PubMed  CAS  Google Scholar 

  36. Kulke MH, Anthony LB, Bushnell DL et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735–752.

    Article  PubMed  Google Scholar 

  37. Sakurai A, Katai M, Yamashita K et al. Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J 2007; 54: 295–302.

    Article  PubMed  Google Scholar 

  38. Triponez F, Goudet P, Dosseh D et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654–662; discussion 663–654.

    Article  PubMed  Google Scholar 

  39. Triponez F, Cadiot G. Non-functioning tumours of the pancreas in MEN1 patients. J Gastrointestin Liver Dis 2007; 16: 295–296.

    PubMed  Google Scholar 

  40. Gauger PG, Scheiman JM, Wamsteker EJ et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003; 90: 748–754.

    Article  PubMed  CAS  Google Scholar 

  41. Langer P, Kann PH, Fendrich V et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004; 28: 1317–1322.

    Article  PubMed  Google Scholar 

  42. Thomas-Marques L, Murat A, Delemer B et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266–273.

    Article  PubMed  Google Scholar 

  43. Kouvaraki MA, Shapiro SE, Cote GJ et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30: 643–653.

    Article  PubMed  Google Scholar 

  44. Hammel PR, Vilgrain V, Terris B et al. Pancreatic involvement in von Hippel–Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel–Lindau. Gastroenterology 2000; 119: 1087–1095.

    Article  PubMed  CAS  Google Scholar 

  45. Libutti SK, Choyke PL, Bartlett DL et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 1998; 124: 1153–1159.

    Article  PubMed  CAS  Google Scholar 

  46. Maddock IR, Moran A, Maher ER et al. A genetic register for von Hippel–Lindau disease. J Med Genet 1996; 33: 120–127.

    Article  PubMed  CAS  Google Scholar 

  47. Rosenau J, Bahr MJ, von Wasielewski R et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002; 73: 386–394.

    Article  PubMed  CAS  Google Scholar 

  48. Le Treut YP, Gregoire E, Belghiti J et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008; 8: 1205–1213.

    Article  PubMed  Google Scholar 

  49. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 585–594.

    Article  PubMed  Google Scholar 

  50. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 131–144.

    Article  PubMed  CAS  Google Scholar 

  51. Yao KA, Talamonti MS, Nemcek A et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130: 677–682; discussion 682–675.

    Article  PubMed  CAS  Google Scholar 

  52. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271–279.

    Article  PubMed  Google Scholar 

  53. King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921–929.

    Article  PubMed  Google Scholar 

  54. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30: 435–441.

    Article  PubMed  CAS  Google Scholar 

  55. Forrer F, Valkema R, Kwekkeboom DJ et al. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 111–129.

    Article  PubMed  CAS  Google Scholar 

  56. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124–2130.

    Article  PubMed  CAS  Google Scholar 

  57. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501–513.

    Article  PubMed  CAS  Google Scholar 

  58. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011; 471: 316–317.

    Article  PubMed  CAS  Google Scholar 

  59. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514–523.

    Article  PubMed  CAS  Google Scholar 

  60. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299–309.

    Article  PubMed  CAS  Google Scholar 

  61. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25–35.

    Article  PubMed  CAS  Google Scholar 

  62. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220–231.

    Article  PubMed  CAS  Google Scholar 

  63. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010; 28: 4425–4433.

    Article  PubMed  CAS  Google Scholar 

  64. Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199–1203.

    Article  PubMed  CAS  Google Scholar 

  65. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753–781.

    Article  PubMed  Google Scholar 

  66. Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689–2696.

    Article  PubMed  CAS  Google Scholar 

  67. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762–4771.

    Article  PubMed  CAS  Google Scholar 

  68. Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 2005; 35: 179–185.

    Article  PubMed  CAS  Google Scholar 

  69. Ramanathan RK, Cnaan A, Hahn RG et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12: 1139–1143.

    Article  PubMed  CAS  Google Scholar 

  70. Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268–275.

    Article  PubMed  CAS  Google Scholar 

  71. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548–3554.

    Article  PubMed  CAS  Google Scholar 

  72. Steinmuller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47–62.

    Article  PubMed  Google Scholar 

  73. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007; 12: 253–270.

    Article  PubMed  CAS  Google Scholar 

  74. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16: 219–224.

    Article  PubMed  CAS  Google Scholar 

  75. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21: 575–581; x.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Images were kindly provided by Dr. Mahmoud Al-Hawary, assistant professor of radiology, University of Michigan, Ann Arbor, MI.

Author information

Authors and Affiliations

  1. Department of Surgery, University of Michigan, 1500 East Medical Center Drive, SPC 5343, Taubman Center TC 2210D, Ann Arbor, MI, 48109-5343, USA

    Rebecca M. Minter & Diane M. Simeone

Authors
  1. Rebecca M. Minter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diane M. Simeone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca M. Minter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minter, R.M., Simeone, D.M. Contemporary Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 16, 435–446 (2012). https://doi.org/10.1007/s11605-011-1693-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-011-1693-5

Keywords

Search

Navigation